D.
"This approval is the most recent example of Abbott's significant strides
against cancer through advanced molecular diagnostics and new treatments to
help patients live longer, healthier lives."

About Fluorescence in situ Hybridization
The FISH technology platform is a system in which genes and chromosomes
are probed by fluorescent-labeled DNA and then illuminated to allow for
clearer identification.
Antares Pharma currently distributes its needle-free injector systems in
more than 30 countries and markets the same technology for use with human
growth hormone through licensees in most major regions of the world.

gvs elmsford

Abbott is a global, broad-based health care company devoted to the
discovery, development, manufacture and marketing of pharmaceuticals and
medical products, including nutritionals, devices and diagnostics.com .

dma gvs

The FDA based its approval on a Premarket Approval Application (PMA) filed
by Abbott in December 2003.7 percent .5 percent. The
company employs more than 60,000 people and markets its products in more than
130 countries.
Based on the evidence provided by the Company in its pre-IND meeting with the
FDA, the Company was granted the right to proceed directly into a Phase II
dose ranging study upon concurrence with the protocol submitted, as well as
conduct only a single Phase III study."
Dr.
Licensees also market an ibuprofen gel using Antares Pharma's ATD(TM)
technology in several major European countries.

sanofi sutures

"UroVysion is significantly more sensitive than conventional methods for
the detection of bladder cancer," said Michael Sarosdy, M., of San Antonio,
Texas, a urologic oncologist and lead investigator of the UroVysion study. Abbott scientists are also exploring FISH's
diagnostic capabilities for cervical, esophageal, melanoma and hematological
cancers.

For more information, visit Antares Pharma's web site at
http://www.antarespharma.

cpg elmsford

Prior to that,
monitoring was done primarily by cystoscopy and urine cytology.g."
OAB is characterized by involuntary muscle contractions leading to loss of
urine, with symptoms including urinary frequency, urgency and urge
incontinence . Securities and
Exchange Commission.

yms cpg

Included in that filing were the results of a 23-
site study of 497 patients presenting with hematuria. "This is an important new tool for clinicians
to fight bladder cancer. It has been shown that by identifying abnormalities in
chromosomal DNA, clinicians can effect better treatments.

uvex cpg

S.com and its needle-free product website,
http://www.

compresses transdermal

, ureter, urethra ,
renal, and/or prostate in males, and further patient follow-up is justified. Over 500,000 people in the United
States have a history of this cancer.
Currently, the market for OAB is dominated by major pharmaceutical companies
such as Pfizer and Ortho-McNeil Pharmaceuticals, a division of Johnson +
Johnson.

uvex welbeck

S. Positive FISH
results in the absence of other signs or symptoms of bladder cancer recurrence
may be evidence of other urinary tract related cancers, e. In 2005
there will also be about 13,000 deaths from bladder cancer in the United
States (about 9,000 men and 4,000 women ).abbott. A
SCRIPT report in 2004 highlighted that OAB is the fastest growing
pharmaceutical sector , which will exceed $11 billion by the year 2008. The Company's AP-1034 formulation is a cosmetic
quality , clear and odorless gel designed to be rapidly absorbed through the
skin following a once-a-day application on the abdomen, shoulders or thighs
with reduced side effects.

transdermal crutches

supllies masterplan

About Bladder Cancer
The American Cancer Society estimates that in 2005 there will be about
63,000 new cases of bladder cancer diagnosed in the United States (about
47,000 men and 16,000 women). While it can affect a person at any age, it is most common
among the elderly, with a prevalence of 33% to 61% in people over age 65.

Statements included in this press release that are not historical in
nature are "forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995.com.

tyrite stopcocks

The test is designed to detect genetic changes in bladder cells in urine
specimens using a proprietary technology known as fluorescence in situ
hybridization or FISH. Urine cytology was also performed and demonstrated a relative
sensitivity of 39.2 percent and a relative specificity of 91.D.

Antares Pharma Files IND for Its First Proprietary Pharmaceutical Product - Transdermal Gel to Treat Overactive Bladder Syndrome

forceps stopcocks

FDA Approves First Gene-Based Test UroVysion(TM) for Diagnosis of Patients Suspected of Having Bladder Cancer

Food and
Drug Administration has approved Abbott 's UroVysion(TM) DNA probe assay for
use as an aid in the initial diagnosis of bladder cancer in patients with
hematuria (blood in urine) suspected of having bladder cancer.
"This new use should allow physicians to make an earlier diagnosis, with
earlier treatment," Dr. A
negative FISH result does not rule out all bladder cancer, nor does it
necessarily mean that an individual will not develop bladder cancer in the
future. This high rate of recurrence requires that patients be
monitored on a regular basis, including up to four times a year for tumor
recurrence.org

EXTON, Pa.

ouc dma

, The U." Mr. Dario Carrara, Managing Director of Antares Pharma's Pharmaceutical
and Formulation Division, stated, "Our development team has done an
outstanding job in completing the filing within the projected timing. I am
confident that they will continue to work with the Agency toward finalizing
the Phase II protocol and then completing the studies with the same diligence
exhibited to date . The Company's current technology platforms include its Advanced
Transdermal Delivery (ATD(TM)) gels, disposable mini-needle injection systems
(VIBEX(TM)), reusable needle-free injection systems (VISION(R) and Valeo(TM)),
and fast-melt oral (Easy Tec(TM)) tablets.

compresses welbeck

The study compared UroVysion performed on
urine samples to cystoscopy/histology testing methods and demonstrated a
clinical sensitivity of 68.6 percent and a clinical specificity of
77.

littmann elmsford

"Studies have shown that early and accurate detection of bladder cancer is
key as thousands die each year of this disease," said Mark S., Antares Pharma Inc.

forceps elmsford

Approximately 50 percent of patients
will experience a recurrence within two years after an initial diagnosis of
bladder cancer.
Abbott's news releases and other information are available at the
company's web site at http://www. We believe this
accomplishment is indicative of our ability to execute on our commercial plans
and bodes well for our future gel-based products . Antares Pharma claims the protection of the Safe Harbor
for forward-looking statements contained in the Private Securities Litigation
Reform Act of 1995.mediject.

uvex cpg

"
In 2001, the FDA cleared UroVysion for use in conjunction with cystoscopy
to monitor patients for the recurrence of bladder cancer. Smoking causes nearly half of the
deaths from bladder cancer among men (48 percent ) and less than a third of
bladder cancer deaths in women (28 percent).

This category is for suppliers to the healthcare industry.

dosages medex

Sarosdy said.
Stover added, "It is especially rewarding to have been granted the right to
proceed expeditiously with our clinical studies.

About Antares Pharma
Antares Pharma is a specialty pharma company focused on the growing
lifestyle products sector and committed to leveraging its multiple drug
delivery platforms to add value to existing drugs and to create new products
and devices.
Antares Pharma's corporate headquarters is in Exton, Pennsylvania , with
subsidiaries performing research, development, manufacturing and product
commercialization activities in Minneapolis, Minnesota and Basel, Switzerland.

dosages littmann

Soloway, M.,
professor, Department of Urology, University of Miami School of Medicine, and
a leading bladder cancer expert. FISH assay results may not be informative if the specimen
quality and/or specimen slide preparation is inadequate .cancer.

welbeck forceps

Product Limitations
The clinical interpretation of any test results should be evaluated within
the context of the patient's medical history and other diagnostic laboratory
test results.

secretions welbeck

With this
approval, UroVysion represents the first gene-based test available for both
diagnosis and monitoring of bladder cancer recurrence. In addition to
UroVysion, FISH is utilized in an FDA-approved device, PathVysion(R), to
quickly identify which patients with late-stage breast cancer are suitable
candidates for Herceptin therapy. Stover, President and CEO of Antares Pharma, commented, "The
submission of Antares Pharma's first proprietary pharmaceutical submission to
the FDA is an important milestone in our specialty pharma strategy. The Company currently has active
partnering programs with several pharmaceutical and distribution companies for
a number of indications and applications, including diabetes, growth
disorders, obesity, female sexual dysfunction and other hormone therapy.

elmsford masterplan

UroVysion shown to be more sensitive than established methods in detecting
bladder cancer

ABBOTT PARK, Ill.
"The FDA's decision is important because it gives physicians a more
powerful diagnostic test than current methods alone to detect one of the most
common urological cancers," said Edward Michael, president, Abbott Molecular .
AP-1034 utilizes Antares Pharma's proprietary Advanced Transdermal
Delivery (ATD(TM)) gel technology designed to allow delivery of active
substances across the skin.

dosages transdermal

The syndrome affects an estimated 17 million people in the
United States, with the highest incidence of occurrence in women of post-
menopausal age. The Company cautions readers that
forward-looking statements are subject to certain risks and uncertainties,
which could cause actual results to differ materially and which are identified
from time to time in the Company's reports filed with the U. Information included on the Company's website is not
incorporated herein by reference or otherwise.

Suppliers for a specific specialty may appear in that particular category; general or wider industry suppliers will be found here.

yms elmsford

Results demonstrated
that UroVysion had greater sensitivity than the most commonly used testing
method to detect bladder cancer. The chance of a man developing this cancer at
any time during his life is about 1 in 30 and for a woman, 1 in 90.

Source of bladder cancer statistics: http://www.
(Amex: AIS), a specialty pharmaceutical company that develops and licenses
drug delivery technology for next-generation lifestyle products, announced
today that it filed an Investigational New Drug (IND) application on Monday,
March 14, 2005, for the Company's first proprietary pharmaceutical product
(AP-1034), oxybutynin ATD(TM) gel for overactive bladder syndrome (OAB).
Jack E. In addition, Antares Pharma
is undertaking development or is conducting research on several product
opportunities that will form the basis of its specialty pharma program.

welbeck yms

---

- - kjjkjk

Loading...

(Note: These pages use the Atlas Content Safeguard System (ACSS) and require that Javascript is enabled for viewing.)